Effect of MA-TCK26D6 on the percentage of mice showing normal physical activity in the mouse thromboembolism model
| Time after thromboplastin injection, min . | No MA, % (n = 47) . | MA-T30E5A2,* % (n = 53) . | MA-TCK26D6, % (n = 53) . |
|---|---|---|---|
| 15 | 30 | 28 | 55† |
| 30 | 38 | 40 | 67† |
| Time after thromboplastin injection, min . | No MA, % (n = 47) . | MA-T30E5A2,* % (n = 53) . | MA-TCK26D6, % (n = 53) . |
|---|---|---|---|
| 15 | 30 | 28 | 55† |
| 30 | 38 | 40 | 67† |
The percentage of mice with normal physical activity was evaluated at 15 and 30 minutes after tPA and thromboplastin injections: 26 mg/kg MA-T30E5A2, 26 mg/kg MA-TCK26D6, or no MA was used
MA-T30E5A2 is an antibody directed against human TAFI showing no cross-reactivity with mouse TAFI.12
Significantly different from respective control mice without MA injection (P < .05).